CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Conditions
Breast Neoplasms - Arthralgia - Arthritis - Genetic Polymorphism
Conditions: official terms
Arthralgia - Breast Neoplasms
Conditions: Keywords
Breast neoplasms, Aromatase inhibitors, Genetic polymorphisms, Arthralgia, Arthritis
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: Aromatase Inhibitor(Femara or Arimidex)
Type: Drug
Overall Status
Recruiting
Summary
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

1. The patient must sign the informed consent.

2. The patient must sign the informed consent of genetic screening test.

3. The patient must be between 18 years old and 80 years old who can make a decision independently.

4. The patient must be post-menopause status.

5. The patient should be the stage 1,2 or 3 of the breast cancer.

6. The test result of the estrogen receptor or progesterone receptor is positive, so the patient should be taking the medication of AI (Aromatase Inhibitor).

Exclusion Criteria:

1. The patient is pre-menopause status.

2. The test result of serum FSH level is below 30mU/ml.

3. The test result of the hormone receptor(ER & PR) is negative or unknown.

4. Patient's breast cancer stage is 4 which has systemic metastatics.
Location
Korea University Anam Hopital
Seoul, Korea, Republic of
Status: Recruiting
Contact: Eun Sook Lee, MD, PhD - 82-2-920-6744 - eslee@korea.ac.kr
Start Date
March 2009
Completion Date
September 2010
Sponsors
Korea University Anam Hospital
Source
Korea University Anam Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page